MDxHealth is a molecular diagnostics company that develops and commercializes innovative tests for cancer assessment and the personalized treatments of patients. Utilizing our proprietary, patented DNA methylation platform and biomarkers, we help address the large and growing unmet medical need by offering tests that aid in the improvement of cancer diagnostics, prognosis and treatment.
About ConfirmMDx for Prostate Cancer
ConfirmMDx is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect associated with the cancerization process at the DNA level. This field effect around a cancer lesion can be present despite having a normal appearance under the microscope.
The test helps urologists:
- Rule out prostate cancer-free men from undergoing unnecessary repeat biopsies
- Rule in high-risk patients who may require repeat biopsies and potential treatment
MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award
MDxHealth's CEO Jan Groen Ph.D. Bolero Interview
MDxHealth & Andros Clinic